Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

Expert Review of Neurotherapeutics

Volumn 9, Issue 3, 2009, Pages 319-321

  Longbrake, Erin E ^b   Racke, Michael K ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

IL 12; IL 23; Multiple sclerosis

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 23; PLACEBO; USTEKINUMAB; ANTIBODY;

ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG SCREENING; IMMUNOLOGY; REVIEW; TREATMENT FAILURE;

ANIMALS; ANTIBODIES; DRUG EVALUATION; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; MULTIPLE SCLEROSIS; TREATMENT FAILURE;

EID: 66449113393     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.9.3.319     Document Type: Article

References (24)

1. + T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103, 4222-4231 (2004).
2. Segal BM, Shevach EM. IL-12 unmasks latent autoimmune disease in resistant mice. J Exp. Med. 184, 771-775 (1996).
3. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med 201, 233-240 (2005).
4. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med 181, 381-386 (1995).
5. Ichikawa M, Koh CS, Inoue A et al. Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide. J Neuroimmunol. 102, 56-66 (2000).
6. Constantinescu CS, Wysocka M, Hilliard B et al. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J. Immunol. 161, 5097-5104 (1998).
7. 't Hart BA, Brok HP, Remarque E et al. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody. J. Immunol. 175, 4761-4768 (2005).
8. Brok HP, Van Meurs M, Blezer E et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J. Immunol. 169, 6554-6563 (2002).
9. Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796-804 (2008).
10. Deshpande P, King IL, Segal BM. IL-12 driven upregulation of β-selectin ligand on myelin-specific T cells is a critical step in an animal model of autoimmune demyelination. J. Neuroimmunol. 173, 35-44 (2006).
11. Bagaeva LV, Williams LP, Segal BM. IL-12 dependent/IFN γ independent expression of CCR5 by myelin-reactive T cells correlates with encephalitogenicity. J Neuroimmunol. 137, 109-116 (2003).
12. Kerfoot SM, Kubes P. Overlapping roles of β-selectin and a 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol. 169, 1000-1006 (2002).
13. Karpus WJ, Lukacs NW, McRae BL et al. An important role for the chemokine macrophage inflammatory protein-1 α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol. 155, 5003-5010 (1995).
14. Yednock TA, Cannon C, Fritz LC et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against a 4 β 1 integrin. Nature 356, 63-66 (1992).
15. Rice GP, Hartung HP, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64, 1336-1342 (2005).
16. Gran B, Zhang GX, Yu S et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol. 169, 7104-7110 (2002).
17. Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp. Med. 187, 537-546 (1998).
18. Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003).
19. Thakker P, Leach MW, Kuang W et al. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol. 178, 2589-2598 (2007).
20. + T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for β-selectin glycoprotein ligand-1. Blood 101, 4775-4782 (2003).
21. van Veen T, Nielsen J, Berkhof J et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol. 190, 157-164 (2007).
22. Windhagen A, Newcombe J, Dangond F et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp. Med. 182, 1985-1996 (1995).
23. Li Y, Chu N, Hu A et al. Increased IL-23pl9 expression in multiple sclerosis lesions and its induction in microglia. Brain 130, 490-501 (2007).
24. Becher B, Durell BG, Noelle RJ. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin. Invest. 112, 1186-1191 (2003).